Furuya Y, Akakura K, Akimoto S, Ito H
Department of Urology, School of Medicine, Chiba University, Chiba, Japan.
Urol Int. 1998 Oct;61(1):17-21. doi: 10.1159/000030277.
The mode of progression in patients with prostate cancer with metastasis to nonregional lymph nodes was examined in order to know whether the site of metastasis effects the prognosis of prostate cancer.
From 1986 to 1995 at the Chiba University Hospital, 205 cases of prostatic cancer with distant metastases were experienced. In 17 of them, nonregional lymph node metastases were observed at the diagnosis, of whom 10 also had bone metastases.
There was no statistical difference in prognosis between 17 patients with nonregional lymph node metastases and remaining 188 patients with metastatic prostate cancer. In all patients metastasized to nonregional lymph nodes, serum prostate-specific antigen and/or prostatic acid phosphatase levels were elevated. Anti-androgen therapy was effective in 15 cases and 5-year survival rate was 45.8%. Patients without bone metastases at the initial diagnosis could survive longer than those with metastases to bone (p < 0.05).
From these observations, endocrine therapy was effective even in patients with distant lymph node metastases.
研究前列腺癌转移至非区域淋巴结患者的进展模式，以了解转移部位是否影响前列腺癌的预后。
1986年至1995年，千叶大学医院共收治205例有远处转移的前列腺癌患者。其中17例在诊断时发现有非区域淋巴结转移，其中10例同时伴有骨转移。
17例有非区域淋巴结转移的患者与其余188例转移性前列腺癌患者的预后无统计学差异。所有转移至非区域淋巴结的患者，血清前列腺特异性抗原和/或前列腺酸性磷酸酶水平均升高。抗雄激素治疗对15例有效，5年生存率为45.8%。初诊时无骨转移的患者比有骨转移的患者存活时间更长（p<0.05）。
基于这些观察结果，内分泌治疗即使对有远处淋巴结转移的患者也有效。
